XstalBio Launches CentuRecon to Accelerate the Delivery of Biologic Drugs
XstalBio Ltd recently announced the launch of CentuRecon, a new patented reconstitution technology that has the potential to revolutionize the preparation of high concentration protein solutions from dry powders and make delivery faster and safer.
Biologic drugs, such as monoclonal antibodies, are a major growth area for the pharmaceutical industry, but their delivery by subcutaneous administration provides unique challenges. CentuRecon enables dry formulations of therapeutic proteins to be prepared for injection at high concentration in minutes, rather than hours, and produces foam-free solutions that maximize the deliverable dose.
CentuRecon works well with standard lyophilized formulations and diluents and with normal vials, cartridges, or dual-chamber syringes. It is particularly beneficial for very high-concentration and/or viscous solutions that may need to be delivered with injection devices. Medical practitioners will find CentuRecon straightforward and cost effective to implement with patients benefiting from fewer injections and shorter visits. Further developments are expected to make self-administration simpler and more convenient. To see CentuRecon in action please view the short video at: http://www.labtube.tv/playvideo.aspx?vid=155993
“We believe CentuRecon is a game-changing technology; uniquely it provides a rapid, safe, and reproducible method for preparing very high-concentration protein solutions from dry powder formulations,” said XstalBio’s R&D Director, Barry D. Moore. “We believe it will open up new clinical opportunities for biologics and become the reconstitution method of choice for R&D scientists. CentuRecon is a good example of how XstalBio’s R&D team is able to develop technologies that provide simple solutions to complex problems.”
XstalBio is a privately held company founded in 2004 and based in Glasgow, Scotland. XstalBio works collaboratively with international clients to help drive biopharmaceuticals and vaccines to market by enabling delivery of products to patients. XstalBio provides its experience, innovative technologies, and expert consultancy to find efficient solutions to complex bioformulation challenges and accelerate the development of biologics. For more information, visit www.xstalbio.com.
Total Page Views: 940
